Postpartum depression (PPD) is depression that occurs after giving birth for up to 12 months. It is a serious disorder affecting 10-20% of mothers (Khadka, 2024).

For most cases of mild to moderate postpartum depression, standard treatment with psychotherapy with or without an antidepressant works well. Treating severe PPD is more challenging. Fortunately, there is a new category of medication for PPD that is intended for severe PPD.

The newest one is zuranolone (trade name is Zurzuvae). Currently, "existing efficacy data are limited to individuals with severe postpartum depression, where long-term outcomes need further study" (Miller, 2025). It has a different mode of action than older antidepressants.

Multiple factors affect GABAa, a nerve receptor in the brain. This receptor is involved in the development of PPD and is a major target for treatment (Sharma, 2024). GABAa is the........

© Psychology Today